TransMedics Group, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from TransMedics Group, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales and profit both grew in each of the last 3 years. Steadier than 96% of Healthcare companies in United States.
- Debt Due Cover Ratio: Debt due within a year is covered 19.3 times by its yearly operating cash. Higher than 89% of Healthcare companies in United States.
- Tangible Assets Ratio: Of every $100 the company owns, $99 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. More tangible than 87% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
$114Over the last 3 years, every $100 of reported profit came with $114 of operating cash.
Lower than 74% of Healthcare companies in United States.
Self-Funding Ratio
0.6×Over the last 3 years its own operating cash paid for 62% of its investment spending (capex); the rest came from other sources such as borrowing, cash reserves or new shares.
Higher than 66% of Healthcare companies in United States.
Cash Locked Ratio
$20For every $100 of sales, $20 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $48 tied up three years earlier.
Less money tied up than 56% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
$44Sales grew 548% in 3 years; of every extra $100 of sales, $44 became extra profit.
Higher than 66% of Healthcare companies in United States.
Asset Productivity Ratio
+548% / +285%In 3 years sales changed by +548% while total assets changed by +285%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
19.3×Debt due within a year is covered 19.3 times by its yearly operating cash.
Higher than 89% of Healthcare companies in United States.
Cash Cushion Ratio
−1%Debt, after subtracting cash, equals 1% of its market value (net debt).
Lower than 69% of Healthcare companies in United States.
Tangible Assets Ratio
99%Of every $100 the company owns, $99 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 87% of Healthcare companies in United States.
Tangible Net Worth Ratio
97%Of every $100 of net worth, $97 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 86% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
TransMedics Group, Inc. owes $0.65 for every $1 it owns. Net profit rose 437% in the year to Dec 2025.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
18.7Investors pay $18.7 for every $1 of TransMedics Group, Inc.'s yearly profit, lower than 67% of Healthcare companies in United States.
P/B ratio
4.82The share price is 4.82 times TransMedics Group, Inc.'s book value per share, higher than 71% of Healthcare companies in United States.
Market cap
$2.5 BThe total market value of all of TransMedics Group, Inc.'s shares at today's price (share price × number of shares), larger than 78% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$518 MWhat TransMedics Group, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$14.94Net worth divided by the number of shares. The share price of $72.06 is 4.8 times this, which is the P/B above.
Return on equity (ROE)
36.3%TransMedics Group, Inc. earned 36.3% on its shareholders' money over the last year, higher than 95% of Healthcare companies in United States.
Owes vs Owns
0.65×TransMedics Group, Inc. owes $0.65 for every $1 it owns (moderate), higher than 68% of Healthcare companies in United States.
Dividend yield
NoneTransMedics Group, Inc. does not currently pay a dividend.
Revenue growth
+37%Revenue rose 37% in the year to Dec 2025, and grew 86% a year on average over 3 years.
Profit growth
+437%Net profit rose 437% in the year to Dec 2025.
Profit margin
31.4%TransMedics Group, Inc. keeps $31 of every $100 of revenue as net profit.
Cash quality
1.01×Cash from TransMedics Group, Inc.'s business was 1.01× its reported profit in the year to Dec 2025 — its profit turned into cash.
Interest cover
7.9×TransMedics Group, Inc.'s operating profit covered its interest costs 7.9 times in the year to Dec 2025.
Cash vs debt
Net debtTransMedics Group, Inc. had $31 M more debt than cash (net debt) at Dec 2025.
Questions
What is TransMedics Group, Inc.'s P/E ratio?
Investors pay $18.7 for every $1 of TransMedics Group, Inc.'s yearly profit, lower than 67% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For TransMedics Group, Inc.: $2.5 B ÷ $518 M (30 Jun 2026) = 4.8.
What is TransMedics Group, Inc.'s return on equity?
TransMedics Group, Inc. earned 36.3% on its shareholders' money over the last year, higher than 95% of Healthcare companies in United States.
How much does TransMedics Group, Inc. owe compared with what it owns?
TransMedics Group, Inc. owes $0.65 for every $1 it owns (moderate), higher than 68% of Healthcare companies in United States.
Does TransMedics Group, Inc. pay a dividend?
No. TransMedics Group, Inc. does not currently pay a dividend.
Is TransMedics Group, Inc.'s revenue growing?
Revenue rose 37% in the year to Dec 2025, and grew 86% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.